Research & Development

29 Nov 2019
- Drug Discovery
- Research & Development
WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus products

By PBR Staff Writer

WuXi ATU Co, a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the development and manufacturing of oncolytic virus products. Under the terms of the collaboration, WuXi ATU will provide overall process development, manufacturing and Investigational New Drug (IND) filing services for GeneMedicine's oncolytic virus products.
27 Nov 2019
Drug Discovery
Research & Development
Lonza and DiNAQOR announce strategic collaboration to advance gene therapy programs for patients with monogenic cardiomyopathies

By PBR Staff Writer

Lonza and DiNAQOR AG, a global gene therapy platform company, announced a strategic collaboration to advance DiNAQOR's preclinical programs for the treatment of cardiac myosin-binding protein-C (MYBPC3) cardiomyopathies, a genetic condition that can result in heart failure.
26 Nov 2019
Drug Discovery
Research & Development
Ferring, Blackstone to invest $570m in gene therapy for bladder cancer

By PBR Staff Writer

Ferring Pharmaceuticals and Blackstone Life Sciences will make a joint investment of more than $570m in an investigational gene therapy called nadofaragene firadenovec (rAd-IFN/Syn3) for bladder cancer patients.
26 Nov 2019
Drug Discovery
Research & Development
CARB-X funds VenatoRx to support development of new class of oral antibiotics to treat multi-drug-resistant gonorrhoea

By PBR Staff Writer

CARB-X is awarding VenatoRx Pharmaceuticals, (Malvern, Pennsylvania, USA) up to US$4.1 million in non-dilutive funding, with the possibility of up to an additional US$8.9 million if certain project milestones are met, to develop a new class of oral antibiotics to treat infections caused by multi-drug-resistant (MDR) Neisseria gonorrhoeae.
25 Nov 2019
Drug Discovery
Research & Development
Novartis to buy The Medicines Company for $9.7bn

By PBR Staff Writer

Novartis has agreed to acquire The Medicines Company for about $9.7bn to add inclisiran, an investigational cholesterol-lowering drug, to its cardiovascular portfolio.
22 Nov 2019
Drug Discovery
Research & Development
Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer

By PBR Staff Writer

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCyte’s Flow Electroporation technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.
22 Nov 2019
Drug Discovery
Research & Development
ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment

By PBR Staff Writer

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizerand Shionogi Limited as shareholders, today announced that the company will be developing the investigational broadly neutralising antibody (bNAb) N6LS for the treatment and prevention of HIV-1, as part of an exclusive licensing agreement between GSK and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
21 Nov 2019
Drug Discovery
Research & Development
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

By PBR Staff Writer

Bristol-Myers Squibb (BMS) has completed the acquisition of US-based biotechnology company Celgene in a cash-cum-stock deal worth around $74bn.
20 Nov 2019
Drug Discovery
Research & Development
CNS Pharmaceuticals acquired worldwide rights for brain cancer drug from Houston Pharmaceuticals

By PBR Staff Writer

CNS Pharmaceuticals, a biotechnology company specializing in the development of novel treatments for brain tumors, completed an agreement with Houston Pharmaceuticals, Inc. ("HPI") to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as Berubicin.
19 Nov 2019
Drug Discovery
Research & Development
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

By PBR Staff Writer

US-based Dicerna Pharmaceuticals and Novo Nordisk have signed a deal worth up to around $607m to discover and develop drugs for liver-related cardio-metabolic diseases.

Drug Discovery

Research & Development

SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody

Atara receives FDA complete response letter for Ebvallo BLA application

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Research & Development

WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus products

Lonza and DiNAQOR announce strategic collaboration to advance gene therapy programs for patients with monogenic cardiomyopathies

Ferring, Blackstone to invest $570m in gene therapy for bladder cancer

CARB-X funds VenatoRx to support development of new class of oral antibiotics to treat multi-drug-resistant gonorrhoea

Novartis to buy The Medicines Company for $9.7bn

Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer

ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment

Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

CNS Pharmaceuticals acquired worldwide rights for brain cancer drug from Houston Pharmaceuticals

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found